MedTrace Logo

High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients

NCT02570399 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-10-06

No results posted yet for this study

Summary

This is a prospective, multicentric, phase II and feasibility study aimed to address early and late side effects of hypofractionated ablative radiotherapy for oligometastatic patients with lymph node metastases for genito-urinary, gastro-intestinal and gynaecological cancer.

Conditions

  • Lymph Node Cancer Metastatic

Interventions

RADIATION

Oligometastatic patients with abdominal-pelvic lymph nodes

Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Ciro Franzese, MD · Istituto Clinico Humanitas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-26
Primary Completion
2019-03-26
Completion
2022-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02570399 on ClinicalTrials.gov